JP2017526700A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526700A5 JP2017526700A5 JP2017513044A JP2017513044A JP2017526700A5 JP 2017526700 A5 JP2017526700 A5 JP 2017526700A5 JP 2017513044 A JP2017513044 A JP 2017513044A JP 2017513044 A JP2017513044 A JP 2017513044A JP 2017526700 A5 JP2017526700 A5 JP 2017526700A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- administered
- monoclonal antibody
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims description 13
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 13
- 229960002756 azacitidine Drugs 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 10
- 229950009791 durvalumab Drugs 0.000 claims description 7
- 206010061818 Disease progression Diseases 0.000 claims description 2
- 229960003852 atezolizumab Drugs 0.000 claims description 2
- 230000005750 disease progression Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 43
- 150000003839 salts Chemical class 0.000 claims 12
- 239000012453 solvate Substances 0.000 claims 12
- 208000035475 disorder Diseases 0.000 claims 9
- 206010033128 Ovarian cancer Diseases 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 229960003301 nivolumab Drugs 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000007894 caplet Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 229950010773 pidilizumab Drugs 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 231100000402 unacceptable toxicity Toxicity 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 description 4
- 238000001802 infusion Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000006842 hematologic response Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462047463P | 2014-09-08 | 2014-09-08 | |
| US62/047,463 | 2014-09-08 | ||
| PCT/US2015/048812 WO2016040238A1 (en) | 2014-09-08 | 2015-09-08 | Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017526700A JP2017526700A (ja) | 2017-09-14 |
| JP2017526700A5 true JP2017526700A5 (enExample) | 2018-03-08 |
Family
ID=54150681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017513044A Pending JP2017526700A (ja) | 2014-09-08 | 2015-09-08 | 抗ｐｄ１若しくは抗ｐｄｌ１モノクローナル抗体と組み合わせてシチジン類似体の経口製剤を使用する疾患または障害の治療方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160067336A1 (enExample) |
| EP (1) | EP3191104A1 (enExample) |
| JP (1) | JP2017526700A (enExample) |
| KR (1) | KR20170045237A (enExample) |
| CN (1) | CN106604745A (enExample) |
| AU (1) | AU2015315435A1 (enExample) |
| CA (1) | CA2960490A1 (enExample) |
| EA (1) | EA201790543A1 (enExample) |
| IL (1) | IL250887A0 (enExample) |
| MX (1) | MX2017002875A (enExample) |
| SG (1) | SG11201701710SA (enExample) |
| WO (1) | WO2016040238A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3081576T3 (pl) | 2013-12-12 | 2020-03-31 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne |
| US10301273B2 (en) | 2014-08-07 | 2019-05-28 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
| WO2016149201A2 (en) * | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| WO2016196389A1 (en) * | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Treatment of renal cell carcinoma |
| BR112018000768A2 (pt) | 2015-07-13 | 2018-09-25 | Cytomx Therapeutics Inc | anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos |
| US11287428B2 (en) | 2016-03-16 | 2022-03-29 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | PD1 and PDL-1 expression during progression from myelodysplastic syndrome to acute myelogenous leukemia |
| EP3468600A4 (en) | 2016-06-10 | 2019-11-13 | IO Therapeutics, Inc. | RECEPTOR-ELECTIVE RETINOID AND REXINOID COMPOUNDS AND IMMUNOMODULATORS FOR CANCER IMMUNOTHERAPY |
| EP3481422A1 (en) * | 2016-07-06 | 2019-05-15 | Pierre Fabre Medicament | Vinflunine and pd1 and/or pdl1 inhibitor as pharmaceutical combination |
| MX2019003755A (es) * | 2016-10-06 | 2019-08-12 | Pfizer | Regimen de dosificacion de avelumab para el tratamiento de cancer. |
| EP4295918A3 (en) | 2016-11-02 | 2024-03-20 | Bristol-Myers Squibb Company | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma |
| EP3589659B1 (en) * | 2017-02-28 | 2025-04-09 | Mayo Foundation for Medical Education and Research | Combinations for use in the treatment of cancer |
| WO2018204374A1 (en) * | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
| EP3624848A1 (en) | 2017-05-19 | 2020-03-25 | Syndax Pharmaceuticals, Inc. | Combination therapies |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| MX2020000467A (es) | 2017-07-13 | 2020-08-03 | Io Therapeutics Inc | Compuestos retinoides y rexinoides inmunomoduladores en combinacion con inmunomoduladores para inmunoterapia contra cancer. |
| CN111148514A (zh) | 2017-08-31 | 2020-05-12 | Io治疗公司 | 与免疫调节剂联合应用于癌症免疫治疗的rar选择性激动剂 |
| US20220008383A1 (en) * | 2018-11-13 | 2022-01-13 | Amy Yee | Compositions and methods of enhancing immunotherapies |
| WO2020180904A1 (en) * | 2019-03-04 | 2020-09-10 | North Carolina State University | Drug delivery for combination of epigenetic modulation and immune checkpoint blockade |
| BR112021025537A2 (pt) | 2019-06-20 | 2022-03-03 | Celgene Quanticel Res Inc | Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para o tratamento de leucemia ou síndrome mielodisplásica |
| KR20210097882A (ko) * | 2020-01-30 | 2021-08-10 | 삼성바이오에피스 주식회사 | 안정한 항-pd-1 항체 약제학적 제제 |
| US20230144385A1 (en) * | 2020-04-07 | 2023-05-11 | Metanoi Therapeutics, Inc. | Ethanolamine formulation for treating epithelial ovarian carcinoma |
| AU2022370354A1 (en) | 2021-10-19 | 2024-05-30 | Akirabio, Inc. | Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers |
| WO2025042742A1 (en) | 2023-08-18 | 2025-02-27 | Bristol-Myers Squibb Company | Compositions comprising antibodies that bind bcma and cd3 and methods of treatment |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR036993A1 (es) * | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| HUE030807T2 (en) * | 2008-09-26 | 2017-05-29 | Dana Farber Cancer Inst Inc | Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications |
| WO2010093435A1 (en) * | 2009-02-10 | 2010-08-19 | Celgene International Sarl | Methods for treating non-small cell lung cancer using 5-azacytidine |
| WO2013043569A1 (en) * | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| US20140357567A1 (en) * | 2011-11-01 | 2014-12-04 | Celgene Corporation | Methods for treating cancers using oral formulations of cytidine analogs |
| EP2958571B1 (en) * | 2013-02-21 | 2024-04-10 | Michele Maio | Dna hypomethylating agents for cancer therapy |
| WO2015035112A1 (en) * | 2013-09-05 | 2015-03-12 | The Johns Hopkins University | Cancer therapy via a combination of epigenetic modulation and immune modulation |
-
2015
- 2015-09-08 CA CA2960490A patent/CA2960490A1/en not_active Abandoned
- 2015-09-08 CN CN201580048157.4A patent/CN106604745A/zh not_active Withdrawn
- 2015-09-08 US US14/847,570 patent/US20160067336A1/en not_active Abandoned
- 2015-09-08 MX MX2017002875A patent/MX2017002875A/es unknown
- 2015-09-08 WO PCT/US2015/048812 patent/WO2016040238A1/en not_active Ceased
- 2015-09-08 EP EP15766985.4A patent/EP3191104A1/en not_active Withdrawn
- 2015-09-08 JP JP2017513044A patent/JP2017526700A/ja active Pending
- 2015-09-08 EA EA201790543A patent/EA201790543A1/ru unknown
- 2015-09-08 SG SG11201701710SA patent/SG11201701710SA/en unknown
- 2015-09-08 AU AU2015315435A patent/AU2015315435A1/en not_active Abandoned
- 2015-09-08 KR KR1020177006031A patent/KR20170045237A/ko not_active Abandoned
-
2017
- 2017-03-02 IL IL250887A patent/IL250887A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017526700A5 (enExample) | ||
| Feagan et al. | Treatment of active Crohn's disease with MLN0002, a humanized antibody to the α4β7 integrin | |
| RU2708374C2 (ru) | Комбинированная терапия для лечения рака | |
| Hwang et al. | A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer | |
| CN108883132A (zh) | 用于治疗癌症的方法 | |
| JP2019517485A5 (enExample) | ||
| JP2019510785A (ja) | 癌を処置する方法 | |
| JP2020519675A5 (enExample) | ||
| JP2021525714A (ja) | 疾患の処置のためのリルゾール口腔内崩壊錠の使用 | |
| KR20140040728A (ko) | Pi3k 억제제 화합물을 사용한 중피종 치료 방법 | |
| JP2020523384A5 (enExample) | ||
| WO2016168730A1 (en) | Combination treatments with seribantumab | |
| US20130331368A1 (en) | Method of treating hepatocellular carcinoma | |
| WO2021129616A1 (zh) | 抗pd-1抗体和组蛋白去乙酰化酶抑制剂的药物组合及其用途、使用方法 | |
| Boardman et al. | A phase I evaluation of extended field radiation therapy with concomitant cisplatin chemotherapy followed by paclitaxel and carboplatin chemotherapy in women with cervical carcinoma metastatic to the para-aortic lymph nodes: an NRG oncology/gynecologic oncology group study | |
| Ghasemi et al. | PPARγ activation by pioglitazone enhances the anti-proliferative effects of doxorubicin on pro-monocytic THP-1 leukemia cells via inducing apoptosis and G2/M cell cycle arrest | |
| Zhang et al. | A randomized phase I study of abemaciclib in Chinese patients with advanced and/or metastatic cancers | |
| WO2019100003A1 (en) | Combination therapy targeting cancer associated with the hedgehog pathway | |
| WO2021213523A1 (zh) | 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途 | |
| Maruyama et al. | A feasibility trial of postoperative adjuvant chemotherapy with S-1, an oral fluoropyrimidine, for elderly patients with non-small cell lung cancer: a report of the Lung Oncology Group in Kyushu (LOGIK) protocol 0901 | |
| JP6948080B2 (ja) | 手術後の肝細胞癌患者を治療するための薬剤の製造における硫酸化オリゴ糖の使用 | |
| Khwaja et al. | High responses rates with single agent belantamab mafodotin in relapsed systemic AL amyloidosis | |
| JP6704594B2 (ja) | 標準化学療法に不応又は不耐で治癒切除不能な進行又は再発癌患者の治療のための医薬 | |
| AU2015242786A1 (en) | Anti-tumor agent containing anti-tumor platinum complex, and anti-tumor effect enhancer | |
| MX2007000971A (es) | Combinaciones de epotilina. |